Coffs Harbour Health Campus

Coffs Harbour, New South Wales 2450

2 studies enrolling now · 13 studies all time

What they study most

Abiraterone Acetate, Advanced Breast Cancer, Androgens, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Cardiovascular Disease, Cutaneous Squamous Cell Carcinoma, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6

Studies at this site

• To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer — Recruiting now
• This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. — Recruiting now
• A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy — Running, not enrolling
• RegoNivo vs Standard of Care Chemotherapy in AGOC — Completed
• Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma — Running, not enrolling
• A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer — Running, not enrolling
• Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer — Completed
• DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma — Completed
• Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer — Running, not enrolling
• Avelumab in First-line NSCLC (JAVELIN Lung 100) — Completed
• A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer — Status unconfirmed
• A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors — Completed